Filing Flows › Revolution Medicines (RVMD) › Guidance & outlook
Revolution Medicines (RVMD) guidance and outlook
Revolution Medicines (RVMD) reaffirmed its guidance on Nov 4, 2026: Stock-based compensation (segment) $270M–$290M for FY2026. Revolution Medicines' 10-Q filed Nov 4, 2026 makes 23 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Stock-based compensation | FY2026 | $270M–$290M | reaffirmed |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- We are a global, commercial-stage oncology company dedicated to discovering, developing and commercializing novel targeted therapies for patients with RAS-addicted cancers.
- We also have other preclinical-stage RAS(ON) Inhibitor clinical development opportunities, including the RAS(ON) mutant-selective inhibitors RMC-0708 (Q61H) and RMC-8839 (G13C) and additional novel targeted approaches for patients with RAS-addicted cancers.
- We are nearing selection of a candidate recommended Phase 2 dose for RMC-5127 and currently expect to share initial clinical monotherapy data in 2027.
- We currently expect to initiate a first-in-human clinical trial evaluating RM-055, a representative from this class of RAS(ON) Inhibitors, in the fourth quarter of 2026.
- We believe our inventory on hand and planned manufacturing position us to meet anticipated market demand.
- Because of this unmet need and the prevalence of RAS as a driver of PDAC, we believe that pancreatic cancer represents a particularly compelling opportunity for RAS-targeted therapies.
- We have completed U.S. enrollment in RASolute 303 and currently expect to complete global enrollment in the first half of 2027;
- We currently expect to complete enrollment in RASolve 301 by the end of November 2026, to enable an expected clinical readout in 2027;
- We plan to continue evaluating RASONQUE in NSCLC in combination with bispecific antibodies targeting both the PD-1/PD-L1 and VEGF axes.
- We currently expect to provide a clinical data update and the trial design for RASonate 312 in the first half of 2027.
- In August 2026, we entered into a multi-part collaboration with BeOne Medicines I GmbH (BeOne) which included a clinical collaboration pursuant to which BeOne plans to evaluate drug combinations incorporating RASONQUE, zoldonrasib, elironrasib and/or RMC-5127 with select clinical-stage oncology assets from BeOne, including the MTA-cooperative PRMT5 inhibitor BGB-58067 and the EGFR × MET × MET trispecific antibody…
- Additionally, in October 2026, we entered into a multi-part clinical collaboration with BMS pursuant to which pumitamig (BNT327), a PD-L1/VEGF bispecific antibody jointly developed by BioNTech and BMS, will be evaluated in four planned study cohorts.
Revolution Medicines' latest quarter
Revolution Medicines, Q3 2026: revenue $198M, operating margin -188.9%, net loss $407M, operating cash flow −$416M. The chart follows the revenue to costs, profit and cash.
Questions
Did Revolution Medicines raise or lower its guidance?
Revolution Medicines (RVMD) reaffirmed its guidance on Nov 4, 2026: Stock-based compensation (segment) $270M–$290M for FY2026.
What does Revolution Medicines expect?
We are a global, commercial-stage oncology company dedicated to discovering, developing and commercializing novel targeted therapies for patients with RAS-addicted cancers. We also have other preclinical-stage RAS(ON) Inhibitor clinical development opportunities, including the RAS(ON) mutant-selective inhibitors RMC-0708 (Q61H) and RMC-8839 (G13C) and additional novel targeted approaches for patients with RAS-addicted cancers. We are nearing selection of a candidate recommended Phase 2 dose for RMC-5127 and currently expect to share initial clinical monotherapy data in 2027.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.